Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus.
Zheng, X., Hudyma, T.W., Martin, S.W., Bergstrom, C., Ding, M., He, F., Romine, J., Poss, M.A., Kadow, J.F., Chang, C.H., Wan, J., Witmer, M.R., Morin, P., Camac, D.M., Sheriff, S., Beno, B.R., Rigat, K.L., Wang, Y.K., Fridell, R., Lemm, J., Qiu, D., Liu, M., Voss, S., Pelosi, L., Roberts, S.B., Gao, M., Knipe, J., Gentles, R.G.(2011) Bioorg Med Chem Lett 21: 2925-2929
- PubMed: 21486696 
- DOI: https://doi.org/10.1016/j.bmcl.2011.03.067
- Primary Citation of Related Structures:  
3Q0Z - PubMed Abstract: 
Herein, we present initial SAR studies on a series of bridged 2-arylindole-based NS5B inhibitors. The introduction of bridging elements between the indole N1 and the ortho-position of the 2-aryl moiety resulted in conformationally constrained heterocycles that possess multiple additional vectors for further exploration. The binding mode and pharmacokinetic (PK) properties of select examples, including: 13-cyclohexyl-6-oxo-6,7-dihydro-5H-indolo[2,1-d][1,4]benzodiazepine-10-carboxylic acid (7) (IC(50)=0.07 μM, %F=18), are reported.
Organizational Affiliation: 
Discovery Chemistry and Candidate Optimization, Bristol Myers Squibb, Research and Development, 5 Research Parkway, Wallingford, CT 06492, USA. xiaofan.zheng@bms.com